Patent · US Active

Hybridoma cell line G250 and its use for producing monoclonal antibodies

US9605075B2 · kind B2 · utility

0Cited by

29References

24Claims

0Family size

Assignee

Wilex AG · DE

Inventors

Egbert Oosterwijk · Nijmegen, NL
Sven Warnaar · Leiden, NL
Stefan Ullrich · Tutzing, DE

Key dates

Filing date	Dec 23, 2008
Grant date	Mar 28, 2017
Priority date	—
Expiry date	Feb 12, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/565
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.